Boehringer Ingelheim is a German pharmaceutical company founded in 1885 in Ingelheim am Rhein. It is headquartered in Ingelheim and operates globally across human pharmaceuticals, animal health, and biopharmaceuticals. The company is privately held and owned by the Boehringer, Liebrecht, and von Baumbach families.
Galux completed a $29 million Series B financing and entered an MOU with OliX Pharmaceuticals to jointly develop a next-generation AI-based siRNA delivery platform. The funding will support GaluxDesign, R&D expansion and preclinical validation.
Deupirfenidone, a deuterated form of pirfenidone, is set to be tested in a phase 3 trial this year after successful phase 2b results. The FDA and European Commission have granted orphan drug designation to support its late-stage development.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
Zealand Pharma reported full-year 2025 revenue of DKK 9.2 billion, bolstered by a significant upfront payment from Roche. The company ended the year with DKK 15.1 billion in cash and set 2026 operating expense guidance between DKK 2.72 billion and DKK 3.3 billion.
The large molecule drug substance CDMO market is expected to grow at approximately 9% CAGR through 2031, driven by rising demand for biologics and biosimilars, streamlined regulatory approval pathways, and increasing FDA and EMA approvals for biologic therapies.
Four biotech companies went public in one week raising nearly $1 billion, signaling a potential thaw in IPO markets after years of quiet activity. Regional life sciences hubs outside Boston and San Francisco are attracting record venture funding, while regulatory uncertainty at FDA continues to concern industry leaders.
AbbVie reported progress on two clinical studies: a Phase 2a trial of ABBV-142 for idiopathic pulmonary fibrosis now recruiting patients, and completion of a JUVÉDERM VOLITE study for facial skin quality improvement.
Boehringer Ingelheim India and NIPER Raebareli have signed an MoU to strengthen pharmaceutical education and research collaboration, including access to the company's open science portal and joint initiatives in drug delivery systems.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07570888 |
This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination. |
NOT_YET_RECRUITING | PHASE4 |
| NCT07553429 |
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07544654 |
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy |
NOT_YET_RECRUITING | PHASE3 |
| NCT07540988 |
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression |
NOT_YET_RECRUITING | PHASE3 |
| NCT07531628 |
A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07526194 |
A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated |
RECRUITING | PHASE1 |
| NCT07513207 |
A Study in Healthy People to Test How Vicadrostat Affects the Heart |
RECRUITING | PHASE1 |
| NCT07497087 |
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07486817 |
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab |
NOT_YET_RECRUITING | PHASE2 |
| NCT07486115 |
A Study to Test How Different Doses of BI 3814916 Are Tolerated by Healthy People |
NOT_YET_RECRUITING | PHASE1 |
